STOCK TITAN

Maravai LifeSciences Holdings (MRVI) DEF 14A Filings

MRVI NASDAQ

Here are the DEF 14A proxy statements from Maravai LifeSciences Holdings, Inc. (MRVI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MRVI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRVI filings page.

Rhea-AI Summary

Maravai LifeSciences Holdings, Inc. is asking shareholders to vote at its virtual 2026 Annual Meeting on May 26, 2026, at 2:30 p.m. Pacific Time. Holders of Class A and Class B common stock as of March 27, 2026 can vote online, by phone or by mail.

Shareholders will elect three Class III directors (Bernd Brust, Gregory T. Lucier and Luke Marker) to terms ending at the 2029 meeting, ratify Deloitte & Touche LLP as auditor for 2026, and cast an advisory say‑on‑pay vote on named executive officer compensation. The proxy also details board structure, committee responsibilities, GTCR’s director nomination rights, and the company’s pay‑for‑performance compensation philosophy, including 2025 leadership transitions and base salaries for key executives.